Is Cotadutide approved as a medicine, and where?

No. Cotadutide is not an approved medicine anywhere. It is handled as a research chemical, with only limited or early-stage human data.

What is Cotadutide studied for?

Cotadutide is most often discussed in the context of weight management. Research has examined Dual GLP-1/glucagon receptor pharmacology, Type 2 diabetes with overweight/obesity (completed phase 2), and Diabetic kidney disease albuminuria biomarkers (completed phase 2b). Being studied for an area does not mean it is proven or approved for it.

Does Cotadutide have human clinical trials?

Only to a limited extent. A small number of early-stage human studies exist, but the evidence is preliminary and Cotadutide is not approved.

Index by category›

Metabolic & Weight Loss

Cotadutide

MEDI0382; MEDI-0382

4 min read · Updated October 7, 2026 · 10 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

Explored forWeight management

In brief · TL;DR

Limited/early human data — not approved

Historical dual GLP-1/GCGR agonist (AstraZeneca/MedImmune). Phase 2 published; discontinued 2023 strategically. Not approved. Different molecule from mazdutide, survodutide, or research-vendor 'cotadutide' framing.

Evidence: Only small/early human studies; not approved.

INN cotadutide; codes MEDI0382 / MEDI-0382; PubChem CID 134694273; CAS 1686108-82-6
Daily subcutaneous dual GLP-1R / GCGR co-agonist developed by AstraZeneca (MedImmune collaborator on early studies)
Phase 2 human data published (T2D/obesity, diabetic kidney disease); PROXYMO NASH truncated after programme stop
Discontinued early 2023 — ClinicalTrials.gov whyStopped cites strategic pipeline considerations, not a new safety signal
No phase 3 completed; no FDA/EMA approval; trial-arm microgram figures are not a self-use regimen

↓ Read the full referenced entry below

Cotadutide (MEDI0382) is AstraZeneca's discontinued dual GLP-1/glucagon receptor agonist with published phase 2 human data in type 2 diabetes, diabetic kidney disease, and exploratory NASH biomarkers. Development stopped in 2023 for strategic pipeline reasons, not a newly observed safety signal. It is not approved and is not an active late-stage programme.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents6

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). It is visible in the wiki but noindexed. Educational reference only — not prescribing or self-use guidance.

Section 1 of 6Overview

Overview

Cotadutide (development codes MEDI0382 / MEDI-0382) is a dual GLP-1 receptor / glucagon receptor (GCGR) co-agonist developed by AstraZeneca (with MedImmune as collaborator on early studies). Clinical protocols used once-daily subcutaneous dosing. PubChem CID 134694273 records CAS 1686108-82-6, formula C₁₆₇H₂₅₂N₄₂O₅₅, and MW about 3728 Da.

Highest completed clinical phase was phase 2. AstraZeneca discontinued the programme in early 2023. ClinicalTrials.gov whyStopped language on terminated follow-on studies cites strategic pipeline considerations and states the stop was not due to any newly observed safety signals. No phase 3 efficacy programme was completed, and no FDA or EMA approval exists.

Not the same medicine as active GLP-1/glucagon duals

Mazdutide and survodutide are other dual GLP-1/glucagon agonists with separate sponsors and still-active or differently staged pipelines. Cotadutide is a discontinued historical candidate, not “the next mazdutide.” There is no head-to-head trial linking these molecules.

Section 2 of 6Clinical development (selected)

Clinical development (selected)

NCT	Phase	Status (dossier cut)	Role
NCT03235050 (opens in a new tab)	2b	Completed (n=834)	T2D + overweight/obesity vs placebo + open-label liraglutide; PMID 34016612 (opens in a new tab)
NCT04515849 (opens in a new tab)	2b	Completed (~248)	CKD + T2D + albuminuria vs placebo + open-label semaglutide; PMID 39218393 (opens in a new tab)
NCT05364931 (opens in a new tab)	2	Completed (n=54)	PROXYMO-ADV non-cirrhotic NASH F2/F3 — Part B (phase 3) not run after discontinue
NCT05517226 (opens in a new tab)	1	Terminated	Hepatic impairment PK — stopped with programme discontinuation
NCT05668936 (opens in a new tab)	1	Terminated	Thorough QTc — stopped with programme discontinuation

Section 3 of 6Key human results (peer-reviewed / registry)

Key human results (peer-reviewed / registry)

Phase 2a — Lancet 2018 (PMID 29945727)

Ambery et al. reported early clinical MEDI0382 work in overweight/obese type 2 diabetes, including ascending-dose and phase 2a glucose-AUC and weight outcomes versus placebo. Treat as early peer-reviewed human data, not a registrational package.

Phase 2b metabolic / hepatic — Diabetes Care 2021 (PMID 34016612; NCT03235050)

Fifty-four-week randomised phase 2b (n=834): cotadutide 100 / 200 / 300 µg daily versus placebo versus open-label liraglutide 1.8 mg. HbA1c and weight endpoints were assessed at weeks 14 and 54; liver biomarkers improved at 300 µg versus placebo in the published comparison (not with liraglutide in the same contrast). Common adverse events included nausea (~35%) and vomiting (~17%), reported to decrease over time. Open-label liraglutide arms do not support labelled superiority claims.

Phase 2b diabetic kidney disease — PMID 39218393 (NCT04515849)

Randomised phase 2b in CKD with T2D and albuminuria. Reported UACR reductions on the order of ~44% (300 µg) and ~50% (600 µg) versus placebo at week 14, with persistence described to week 26 in abstract/synthesis framing. Keep numbers tied to the cited paper; this is phase 2 biomarker evidence, not an approved kidney indication.

PROXYMO-ADV NASH — NCT05364931 / EudraCT 2021-005484-53

Originally framed as a two-part phase IIb/III programme. After discontinuation, Part A continued for safety, with efficacy treated as exploratory; Part B (phase 3) was not conducted. The trial completed in 2024; EU results were posted in 2025. Do not claim NASH efficacy approval or a completed phase 3 NASH package from this truncated programme.

Section 4 of 6Claims vs evidence

Claims vs evidence

Claim	Assessment
Dual GLP-1 / glucagon agonist; INN cotadutide = MEDI0382	Supported (Lancet; Diabetes Care; PubChem; CT.gov)
Published phase 2 human data (T2D, DKD)	Supported (PMID 29945727, 34016612, 39218393)
Discontinued 2023 for strategic reasons (not a new safety signal)	Supported (CT.gov whyStopped)
Phase 3 completed / approved product	False
Superior overall to liraglutide or semaglutide	Weak / context-only — open-label comparators in phase 2b
Active research-vendor “cotadutide peptide” equals the clinical candidate	Reject framing — discontinued investigational drug, not a research-reagent monograph use-case
PROXYMO proves NASH phase 3 efficacy	Unsupported — exploratory/safety after discontinue; Part B never run

Section 5 of 6Related pages

Mazdutide, Survodutide — other GLP-1/glucagon dual agonists (different molecules)
Semaglutide, Liraglutide — GLP-1 receptor agonists used as open-label comparators in cotadutide phase 2b
Exenatide — earlier GLP-1 lineage context

Section 6 of 6What this page intentionally omits

What this page intentionally omits

Any self-use dose, titration schedule, or reconstitution protocol
Active-pipeline marketing tone for a discontinued programme
Equating vendor “research peptide” listings with the AstraZeneca clinical candidate

References10

References

1.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese subjects with type 2 diabetes — phase 2a — Ambery P, et al., The Lancet, 2018. source
2.
Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes — phase 2b — Nahra R, et al., Diabetes Care, 2021. source
3.
Cotadutide in diabetic kidney disease — phase 2b — PubMed, 2024. source
4.
Phase 2b T2D / overweight-obesity trial (NCT03235050) — ClinicalTrials.gov. source
5.
Phase 2b CKD with T2D and albuminuria (NCT04515849) — ClinicalTrials.gov. source
6.
PROXYMO-ADV non-cirrhotic NASH (NCT05364931) — ClinicalTrials.gov. source
7.
Hepatic impairment PK — terminated after discontinuation (NCT05517226) — ClinicalTrials.gov. source
8.
Thorough QTc — terminated after discontinuation (NCT05668936) — ClinicalTrials.gov. source
9.
EudraCT 2021-005484-53 results (PROXYMO-ADV) source
10.
PubChem Compound Summary for CID 134694273, Cotadutide — PubChem. source

Frequently asked questions4

Frequently asked questions

What is Cotadutide?: Cotadutide (MEDI0382) is AstraZeneca's discontinued dual GLP-1/glucagon receptor agonist with published phase 2 human data in type 2 diabetes, diabetic kidney disease, and exploratory NASH biomarkers. Development stopped in 2023 for strategic pipeline reasons, not a newly observed safety signal. It is not approved and is not an active late-stage programme.
Is Cotadutide approved as a medicine, and where?: No. Cotadutide is not an approved medicine anywhere. It is handled as a research chemical, with only limited or early-stage human data.
What is Cotadutide studied for?: Cotadutide is most often discussed in the context of weight management. Research has examined Dual GLP-1/glucagon receptor pharmacology, Type 2 diabetes with overweight/obesity (completed phase 2), and Diabetic kidney disease albuminuria biomarkers (completed phase 2b). Being studied for an area does not mean it is proven or approved for it.
Does Cotadutide have human clinical trials?: Only to a limited extent. A small number of early-stage human studies exist, but the evidence is preliminary and Cotadutide is not approved.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Cotadutide is a research chemical not approved for human use. Consult a qualified healthcare professional before making health decisions.

References

Frequently asked questions

Related in Metabolic & Weight Loss